Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review

Lenvatinib plus transarterial chemoembolization (TACE)have become the first choice for patients with hepatocellular carcinoma (HCC) that are unsuitable for TACE. Sorafenib plus TACE therapy for patients with portal vein tumor thrombus (PVTT) achieved positive results. However, Lenvatinib plus TACE a...

Full description

Bibliographic Details
Main Authors: Liwei Sun, Xuelong Xu, Fanguang Meng, Qian Liu, Hankang Wang, Xiaodong Li, Guijie Li, Feng Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
lenvatinib
transarterial chemoembolization
immune checkpoint programmed death factor 1 inhibitors
immune checkpoint inhibitors
unresectable hepatocellular carcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.980214/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.980214/full

Similar Items